139389-29-0

Basic information

• Product Name: 6-(4-FLUOROPHENYL)-2-METHYLIMIDAZO[2,1-B]THIAZOLE-5-CARBOXALDEHYDE
• Synonyms: 6-(4-FLUOROPHENYL)-2-METHYLIMIDAZO[2,1-B]THIAZOLE-5-CARBOXALDEHYDE
• CAS NO: 139389-29-0
• Molecular Formula: C₁₃H₉FN₂OS
• Molecular Weight: 0
• Mol File: 139389-29-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-(4-FLUOROPHENYL)-2-METHYLIMIDAZO[2,1-B]THIAZOLE-5-CARBOXALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-FLUOROPHENYL)-2-METHYLIMIDAZO[2,1-B]THIAZOLE-5-CARBOXALDEHYDE(139389-29-0)
• EPA Substance Registry System: 6-(4-FLUOROPHENYL)-2-METHYLIMIDAZO[2,1-B]THIAZOLE-5-CARBOXALDEHYDE(139389-29-0)

Safety Data

• Hazardous Substances Data: 139389-29-0(Hazardous Substances Data)

Upstream product

• 403-29-2 2-bromo-4'-fluoroacetophenone 
• 139360-16-0 6-(4-fluorophenyl)-2-methylimidazo[2,1-b][1,3]thiazole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1257653-78-3 (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 1336804-63-7 NSC 747107 

Relevant articles and documents

Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors

The activity of a series of imidazo[2,1-b]thiazole guanylhydrazones as inhibitors of p90 ribosomal S6 kinase 2 (RSK2) is described. It was found that a small subset of compounds show both potent inhibition of RSK2 kinase activity and tumor cell growth in vitro. Detailed study of one of the most active compounds indicates a high degree of selectivity for inhibition of RSK2 compared to a spectrum of other related kinases. Selective inhibition of the MCF-7 breast tumor cell line compared to MCF-10A non-transformed cells, as well as selective inhibition of the biomarker GSK3 provides evidence that the compounds can affect the RSK2 target in cells.

Synthesis of imidazothiazole-chalcone derivatives as anticancer and apoptosis inducing agents

A new class of imidazo[2,1-b]thiazole chalcone derivatives were synthesized and evaluated for their anticancer activity. These chalcone derivatives show promising activity, with logGI50 values ranging from -7.51 to -4.00. The detailed biological aspects of these derivatives toward the MCF-7 cell line were studied. Interestingly, these chalcone derivatives induced G 0/G1-phase cell-cycle arrest, down-regulation of G 1-phase cell-cycle regulatory proteins such as cyclin D1 and cyclin E1, and up-regulation of CDK4. Moreover, these compounds elicit the characteristic features of apoptosis such as enhancement in the levels of p53, p21, and p27, suppression of NF-κB, and up-regulation of caspase-9. One of these chalcone derivatives, 3d, is potentially well suited for detailed biological studies, either alone or in combination with existing therapies. Breaking the cycle: We undertook an extensive examination of the ability of a series of new chalcone derivatives to regulate the cell cycle and to induce apoptosis in various cancer cell lines. Compound 3d is a particularly suitable candidate for further detailed biological investigations, especially in the treatment of breast cancer.